Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.13) per share for the quarter.
Unicycive Therapeutics Stock Performance
UNCY opened at $0.64 on Wednesday. The company has a market cap of $65.97 million, a price-to-earnings ratio of -0.66 and a beta of 2.26. Unicycive Therapeutics has a one year low of $0.20 and a one year high of $1.60. The business’s fifty day moving average is $0.59 and its two-hundred day moving average is $0.56.
Wall Street Analyst Weigh In
Separately, HC Wainwright reissued a “buy” rating and issued a $4.00 price objective on shares of Unicycive Therapeutics in a research note on Wednesday, January 29th.
About Unicycive Therapeutics
Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.
Further Reading
- Five stocks we like better than Unicycive Therapeutics
- 3 Best Fintech Stocks for a Portfolio Boost
- Innovation Incubators: Survey of Entrepreneurs Reveals The Cities Most Supportive of Startups
- Energy and Oil Stocks Explained
- NVIDIA Insiders Sell: This Is What It Means for the Market
- What Does Downgrade Mean in Investing?
- Space Stocks Bottoming: Which Are Positioned Best for a Bounce?
Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
